24 May 2023 in Pediatric Nephrology
7 October 2024 in The Turkish Journal of Pediatrics
Background. ZFYVE19 mutation has been recently identified as one of the non-syndromic causes of cholestasis. It is associated with elevated gamma-glutamyl transferase levels and is likely a cause of neonatal-onset and intrahepatic cholestasis. Case. Here, we report a rare case of ZFYVE19 defect, confirmed by whole exome sequencing (WES). Our patient, who is currently 4 years old, presented to us at the age of 2 years with elevated levels of serum transaminases and bilirubin. WES revealed a homozygous ZFYVE19 mutation despite preserved synthetic liver function. This gene has recently been identified in the literature as a cause of non-classical progressive familial intrahepatic cholestasis (OMIM # 619849). Treatment with an appropriate dose of ursodeoxycholic acid resulted in the regression of elevated liver enzymes and itching. The patient’s body mass index progressively increased throughout the treatment period. No medication side effects were observed at any point. Currently, the patient remains asymptomatic during follow-up. Conclusion. We have identified the ZFYVE19 mutation as a variant that is not accompanied by any other symptoms. However, we have limited knowledge about the progression of the disease and are closely monitoring the patient for potential liver-related issues. Using WES in cases of undiagnosed liver enzyme elevations or cholestasis can help identify new genes and improve our understanding of the underlying pathophysiology.
1 January 2025 in Pediatrics International
22 May 2026 in Turkish Archives of Pediatrics
Objective: This study aimed to evaluate the discriminatory performance of hemogram-derived inflammatory parameters in distinguishing pediatric eosinophilic esophagitis (EoE) from symptomatic controls. To determine their potential value as non-invasive tools for longitudinal monitoring, whether these markers correlate with endoscopic and histologic activity during follow-up was also assessed. Methods: This retrospective, longitudinal study included pediatric patients who underwent upper gastrointestinal endoscopy at a tertiary pediatric gastroenterology center between August 2022 and August 2025. Children presenting with dysphagia, vomiting, or abdominal pain who had esophageal, gastric, and duodenal biopsies were evaluated. Eosinophilic esophagitis was diagnosed based on symptoms and the presence of ≥15 eosinophils per high-power field in esophageal biopsies. Symptomatic children with similar age and sex distribution without esophageal eosinophilia served as controls. Hemogram results obtained within 1 week before each endoscopy were analyzed. Hemogram-derived indices (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, derived neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index [SIRI], aggregate index of systemic inflammation, mean platelet volume-to-lymphocyte ratio, mean platelet volume-to-platelet ratio, and red cell distribution width-to-platelet ratio) were calculated. Diagnostic performance was assessed using receiver-operating characteristic analyses, and associations with endoscopic and histologic findings were examined using linear mixed-effects models. Results: Children with EoE showed significantly higher absolute eosinophil counts and markedly elevated SIRI values at diagnosis compared with controls (P < .001). Systemic inflammation response index demonstrated excellent discriminatory performance, whereas most other hemogram-derived indices showed limited accuracy. During follow-up, none of the hemo- gram-derived parameters—including SIRI—correlated with endoscopic or histologic activity. Conclusion: Systemic inflammation response index demonstrated high discriminatory performance in distinguishing pediatric EoE from symptomatic controls, but showed no association with longitudinal disease activity. Endoscopic and histologic assessments remain essential for diagnosis and monitoring.
30 June 2026 in Turkish Journal of Pediatric Disease
Objective: The aim of this study was to compare health-related quality of life (QoL) and anxiety/depressive symptoms in healthy siblings of children with celiac disease (CD) with age- and gender-similar healthy siblings of children without chronic illness. Materials and Methods: This controlled cross-sectional study, conducted in a pediatric gastroenterology and child psychiatry setting at a tertiary-care hospital, enrolled healthy siblings aged 8–17 years into a CD-sibling group (n=70) and a control group (n=70). Sociodemographic data were collected using a standardized form, QoL was assessed using the Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales, and psychiatric symptoms were assessed using the Revised Child Anxiety and Depression Scale (RCADS). Between-group comparisons and Spearman rank correlations were used, and predictors of total anxiety and psychosocial QoL were examined using univariable and multivariable linear regression. Results: Sociodemographic and familial characteristics were largely comparable between groups. Compared with controls, the CD-sibling group had higher total anxiety scores (p=0.007), whereas depressive symptoms were similar between groups (p=0.758). Psychosocial and total QoL were lower in the CD-sibling group (both p<0.001), while physical QoL did not differ between groups (p=0.201). In multivariable models within the CD-sibling group, longer time since diagnosis and maternal psychiatric disorder independently predicted higher anxiety and poorer psychosocial QoL, whereas a greater number of siblings predicted lower anxiety and better psychosocial QoL. Conclusion: Healthy siblings of children with CD experience increased anxiety and reduced psychosocial/total QoL, underscoring the importance of family-centered monitoring that includes sibling well-being and maternal mental health.
16 July 2026 in Journal of Pediatric Gastroenterology and Nutrition